Form 4: Lacey Reports Share Conversion at Provectus Biopharmaceuticals

John Lacey III reports a conversion of Series D-1 Convertible Preferred Stock into Common Stock at Provectus Biopharmaceuticals, Inc.

Summary

• John Lacey III, a Director at Provectus Biopharmaceuticals, Inc. (PVCT), has reported a transaction on June 30, 2026.
• The transaction involved the conversion of 48,917 shares of Series D-1 Convertible Preferred Stock into 489,170 shares of Common Stock.
• This conversion occurred at a price of $0 per share for the preferred stock, with the underlying common stock being valued at $0.
• The Series D-1 Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The preferred stock is set to automatically convert into Common Stock on December 31, 2028, unless converted earlier.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a conversion of existing securities rather than a new investment or a sale of shares, with no immediate financial impact reported.

Positives

• Conversion of preferred stock into a larger number of common shares can indicate a positive step towards equity restructuring or a precursor to future value realization.
• The automatic conversion date provides a clear timeline for the full conversion into common stock.

Negatives

• The transaction is a conversion, not a purchase, and the reported price of $0 for the preferred stock and underlying common stock suggests no new capital was raised in this specific transaction.
• The conversion is into common stock, which may dilute existing common shareholders if not accompanied by a corresponding increase in company value.

Risks

• The Series D-1 Convertible Preferred Stock may not convert if certain conditions are not met before the automatic conversion date.
• The value of the underlying common stock could fluctuate significantly before the automatic conversion date, impacting the effective value of the conversion.

Future Outlook

The Series D-1 Convertible Preferred Stock is scheduled to automatically convert into Common Stock on December 31, 2028, unless an earlier conversion occurs.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, such as stock conversions. This filing indicates a change in the capital structure of Provectus Biopharmaceuticals, Inc. as preferred stock is converted into common stock, a common event for companies managing different classes of equity.

Stakeholder Impact

• Shareholders may experience dilution if the conversion of preferred stock to common stock is not matched by a proportional increase in the company's market value.
• The conversion impacts the equity structure, potentially altering voting rights and ownership percentages for existing common stockholders.

Next Steps

• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless converted earlier.

Key Dates

Keywords

Form 4, Provectus Biopharmaceuticals, PVCT, John Lacey III, Convertible Preferred Stock, Common Stock, Share Conversion, SEC Filing, Insider Transaction